TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20007996

Group type: COMPARATOR
Intervention: Filgrastim (FIL) at a daily dose of 5 mug/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (PEG) at a single fixed dose of 6 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Filgrastim (FIL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (PEG)
Number of subjects: 80
Study: 17180356

Group type: EXPERIMENTAL
Intervention: Artificial cervical disc replacement
Number of subjects: 24

Group type: COMPARATOR
Intervention: Interbody fusion
Number of subjects: 24
Study: 16756652

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 9 schools) with two additional physical education classes per week, short PA breaks during lessons, PA homework, and adaptation of recreational areas.
Number of subjects: 15
Study: 12537034

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 19
Study: 10799425

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (500 mg daily for nine weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (FO unsupplemented children)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation
Number of subjects: 10
Study: 9735591

Group type: EXPERIMENTAL
Intervention: Dry heat exposure (Gr A, N = 5) at 41.3 +/- 0.6 degrees C DB, 40-50% RH
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Humid heat exposure (Gr B, N = 6) at 39.2 +/- 0.6 degrees C DB, 70-80% RH
Number of subjects: 11
Study: 1640192

Group type: EXPERIMENTAL
Intervention: Theophylline + Metoprolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theophylline + Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metoprolol + Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 24
Study: 6667282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Beta-blockade (propanolol 160 mg/day)
Number of subjects: 16
Study: 31305878

Group type: EXPERIMENTAL
Intervention: Social media use
Number of subjects: 3826

Group type: EXPERIMENTAL
Intervention: Computer use
Number of subjects: 3826

Group type: EXPERIMENTAL
Intervention: Social media use (within-person association)
Number of subjects: 3826

Group type: EXPERIMENTAL
Intervention: Television use (within-person association)
Number of subjects: 3826
Study: 29642136

Group type: EXPERIMENTAL
Intervention: Cervical Disc Replacement (CDR)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion (ACDF)
Number of subjects: 253
Study: 26732683

Group type: EXPERIMENTAL
Intervention: Mefloquine (15 mg/kg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 25326927

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Inpatient care
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Other medications
Number of subjects: 367
Study: 22269152

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus Fenofibrate 160 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 180
Study: 20303247

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg plus qd salmeterol 50 microg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg plus bid salmeterol 50 microg
Number of subjects: 95

Group type: COMPARATOR
Intervention: Tiotropium or salmeterol alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination therapies including salmeterol qd or bid
Number of subjects: 95
Study: 17710485

Group type: EXPERIMENTAL
Intervention: 40 mg of prednisolone intravenously for 3 days (steroid group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 31
Study: 15837772

Group type: EXPERIMENTAL
Intervention: Racol (RAC) formula rich in omega-3 PUFAs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ensure Liquid (control)
Number of subjects: 28
Study: 11949746

Group type: EXPERIMENTAL
Intervention: Suction (no water seal)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Water seal
Number of subjects: 52
Study: 9452942

Group type: EXPERIMENTAL
Intervention: Donepezil (up to 10 mg/day)
Number of subjects: 133
Study: 8578163

Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg every morning for 14 days) + Amoxicillin (500 mg oral suspension four times daily for 11 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lansoprazole (60 mg every morning for 14 days)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Lansoprazole + Amoxicillin
Number of subjects: 65
Study: 2804254

Group type: EXPERIMENTAL
Intervention: Clindamycin in Vehicle‐N (Neutrogena)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cleocin‐T
Number of subjects: 12
Study: 349673

Group type: EXPERIMENTAL
Intervention: Enzyme-containing chewing gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 20
Study: 31768768

Group type: EXPERIMENTAL
Intervention: Unfocused extracorporeal shockwave therapy (3,000 electrohydraulic-generated shockwaves at 0.3 mJ/mm2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (contralateral forearm)
Number of subjects: 12
Study: 27383196

Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD, 50% carbohydrates, 33% fat, including 57g/day of pistachios)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Isocaloric control diet (CD, 55% carbohydrates and 30% fat)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD)
Number of subjects: 49
Study: 26414670

Group type: EXPERIMENTAL
Intervention: Depression Medication Choice (DMC)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 301
Study: 23344768

Group type: EXPERIMENTAL
Intervention: Reversed C sternotomy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional sternotomy
Number of subjects: 35
Study: 22238745

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 38
Study: 19920719

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 182
Study: 16953853

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EPIDURAL)
Number of subjects: 992

Group type: COMPARATOR
Intervention: Other methods of pain relief including continuous midwifery support (CMS)
Number of subjects: 992
Study: 15193681

Group type: EXPERIMENTAL
Intervention: Baseline quartile of echocardiographic LVM indexed to body surface area
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Baseline echocardiographic LVM
Number of subjects: 3042

Group type: EXPERIMENTAL
Intervention: Baseline electrocardiographic LVM
Number of subjects: 3042
Study: 11319199

Group type: EXPERIMENTAL
Intervention: Treadmill exercise among normal volunteers
Number of subjects: 107

Group type: COMPARATOR
Intervention: Treadmill exercise among CAD patients
Number of subjects: 107
Study: 9288516

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia (CCP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 42
Study: 8314512

Group type: EXPERIMENTAL
Intervention: Postprandial response after a meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Infusion of mebeverine hydrochloride into the sigmoid colon
Number of subjects: 16
Study: 2894246

Group type: EXPERIMENTAL
Intervention: Nipradilol (9 mg)
Number of subjects: 8
Study: 29406814

Group type: EXPERIMENTAL
Intervention: Video education (n=51)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Skill demonstration (control group; n=63)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 129

Group type: COMPARATOR
Intervention: Skill demonstration
Number of subjects: 129
Study: 27769675

Group type: EXPERIMENTAL
Intervention: 4 mL liposomal bupivacaine (13.3 mg/mL)
Number of subjects: 95

Group type: COMPARATOR
Intervention: 4 mL 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 95
Study: 25439367

Group type: EXPERIMENTAL
Intervention: SMART (single budesonide‐formoterol inhaler as maintenance and reliever therapy)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard therapy (fixed‐dose regimen with salbutamol as reliever)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: SMART
Number of subjects: 303
Study: 22444829

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy (0.5 mg, administered monthly)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Standard fluence (SF) verteporfin PDT plus ranibizumab
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Reduced fluence (RF) verteporfin PDT plus ranibizumab
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Verteporfin SF
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Verteporfin RF
Number of subjects: 321

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Combination therapy (verteporfin SF or RF)
Number of subjects: 321
Study: 20651204

Group type: EXPERIMENTAL
Intervention: Group A: 300 mg I/mL, 50 mL contrast material followed by a 20-mL saline bolus at 3.0 mL/s
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group B: 300 mg I/mL, 100 mL contrast material at 3.0 mL/s
Number of subjects: 100
Study: 18768944

Group type: EXPERIMENTAL
Intervention: Appropriate ICD shock
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Inappropriate ICD shock
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Appropriate ICD shock (survivors > 24 hours)
Number of subjects: 811
Study: 16803614

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12749500

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITNs) with community effect considered
Number of subjects: 0
Study: 11040249

Group type: EXPERIMENTAL
Intervention: High sodium diet
Number of subjects: 65

Group type: COMPARATOR
Intervention: Low sodium diet
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Salt-insensitive hypertensive patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Salt-sensitive hypertensive patients
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Changes in FE(Li)
Number of subjects: 65
Study: 8817986

Group type: EXPERIMENTAL
Intervention: Pneumatic Ventricular Assist Device (VAD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Venoarterial Bypass (VAB) with Percutaneous Cardiopulmonary Support (PCPS)
Number of subjects: 28
Study: 1582239

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 49

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 49
Study: 2866960

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 20
Study: 31238710

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 69
Study: 29319646

Group type: EXPERIMENTAL
Intervention: Telenursing (weekly phone calls for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (one follow-up phone call after 12 weeks)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Telenursing
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 26832451

Group type: EXPERIMENTAL
Intervention: Self-affirmation following ego depletion
Number of subjects: 183

Group type: COMPARATOR
Intervention: Ego depletion without self-affirmation
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Self-affirmation without ego depletion
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (no self-affirmation and no ego depletion)
Number of subjects: 183
Study: 24954166

Group type: EXPERIMENTAL
Intervention: TRV130 (1.5mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TRV130 (3mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TRV130 (4.5mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Morphine (10mg)
Number of subjects: 30
Study: 23129601

Group type: EXPERIMENTAL
Intervention: Canakinumab 5 mg
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Canakinumab 15 mg
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 556

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 556
Study: 20704110

Group type: COMPARATOR
Intervention: TGF‐β2 serum protein levels
Number of subjects: 63

Group type: COMPARATOR
Intervention: TGF‐β3 serum protein levels
Number of subjects: 63

Group type: COMPARATOR
Intervention: Kellgren‐Lawrence radiographic grading
Number of subjects: 63

Group type: COMPARATOR
Intervention: WOMAC scale
Number of subjects: 63

Group type: COMPARATOR
Intervention: TIMP‐1 levels
Number of subjects: 63

Group type: COMPARATOR
Intervention: MMP‐2 and ‐9 activities
Number of subjects: 63
Study: 18554189

Group type: EXPERIMENTAL
Intervention: Clearfil SE BOND (SB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (CH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20
Study: 16236035

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 12440353

Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical)
Number of subjects: 3277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3277
Study: 10088139

Group type: EXPERIMENTAL
Intervention: Pindolol 7.5 mg/day with TSD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo with TSD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pindolol with TSD
Number of subjects: 40
Study: 7582879

Group type: EXPERIMENTAL
Intervention: Relatives of probands with OCD and MDD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relatives of probands with OCD and GAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relatives of probands with OCD
Number of subjects: 0
Study: 2075854

Group type: EXPERIMENTAL
Intervention: Short form of the Alcohol Expectancy Questionnaire‐Adolescent Form (27 items)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Long form of the Alcohol Expectancy Questionnaire‐Adolescent Form (7 scales)
Number of subjects: 377
Study: 7025683

Group type: EXPERIMENTAL
Intervention: CCVPP (cyclophosphamide‐vinblastine‐procarbazine‐prednisone with CCNU)
Number of subjects: 152

Group type: COMPARATOR
Intervention: CVPP (cyclophosphamide‐vinblastine‐procarbazine‐prednisone without CCNU)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combined multidrug chemotherapy
Number of subjects: 152
Study: 31819377

Group type: EXPERIMENTAL
Intervention: Combined 25‐G pars plana vitrectomy (PPV) with intravitreal dexamethasone implant (DXI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard 25‐G PPV with ERM peeling only (control group)
Number of subjects: 40
Study: 29097876

Group type: EXPERIMENTAL
Intervention: HBV vaccination after screening
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly defined)
Number of subjects: 1215
Study: 26493248

Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 10026

Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 10026
Study: 24066730

Group type: EXPERIMENTAL
Intervention: Quality HTN-CVD care package delivered through private health facilities
Number of subjects: 912

Group type: COMPARATOR
Intervention: Current practice at private health facilities
Number of subjects: 912
Study: 21842352

Group type: EXPERIMENTAL
Intervention: Interdisciplinary research interventions related to functional competence and health promotion.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised controlled intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal cohort follow‐up study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross‐sectional comparative studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prospective intervention studies
Number of subjects: 0
Study: 19705400

Group type: EXPERIMENTAL
Intervention: Ultrasound exposure at any time during fetal life
Number of subjects: 4458

Group type: COMPARATOR
Intervention: Ultrasound exposure in the second trimester
Number of subjects: 4458
Study: 17234519

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sitaxsentan 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 48
Study: 15200998

Group type: EXPERIMENTAL
Intervention: Chemotherapy (C), 192 patients, three 3-weekly cycles of cisplatin/vindesine, mitomycin/ifosfamide/cisplatin, mitomycin/vinblastine/cisplatin or vinorelbine/cisplatin.
Number of subjects: 381

Group type: COMPARATOR
Intervention: No chemotherapy (NoC), 189 patients.
Number of subjects: 381
Study: 11800186

Group type: EXPERIMENTAL
Intervention: Single stimulus engagement (SSE) preference assessment
Number of subjects: 4
Study: 9555596

Group type: EXPERIMENTAL
Intervention: Risperidone (RIS) 6.9 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Haloperidol and Amitriptyline (HAL/AMI) 9 mg and 180 mg respectively
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Risperidone (RIS)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Haloperidol and Amitriptyline (HAL/AMI)
Number of subjects: 123
Study: 8041438

Group type: EXPERIMENTAL
Intervention: Magnetic resonance angiography (MRA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Transfemoral four-vessel angiography (conventional angiography)
Number of subjects: 54
Study: 2839442

Group type: COMPARATOR
Intervention: Conventional daily radiation (5 x W) - 5 daily fractions of 2 Gy each to a total dose of 60 Gy in 6 weeks, protecting the spinal cord at 45 Gy.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Once‐a‐week radiation (1 x W) - one weekly fraction of 5 Gy each to a total tumor dose of 60 Gy in 12 weeks, protecting the spinal cord at 30 Gy.
Number of subjects: 150
Study: 31763943

Group type: EXPERIMENTAL
Intervention: Polymyxin B 25 mg IV-RLP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polymyxin B 50 mg IV-RLP
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Polymyxin B 300 mg IV-RLP
Number of subjects: 9
Study: 28600107

Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 969

Group type: COMPARATOR
Intervention: Mail
Number of subjects: 969

Group type: COMPARATOR
Intervention: E-Mail
Number of subjects: 969
Study: 25403578

Group type: COMPARATOR
Intervention: FOLFOX4 (oxaliplatin 85 mg/m²)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: FOLFOX7 (oxaliplatin 130 mg/m²) followed by FOLFIRI (irinotecan 180 mg/m²)
Number of subjects: 284
Study: 23598459

Group type: EXPERIMENTAL
Intervention: Diuretic adjustment according to the AAD (algorithm de ajuste de diurético)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional adjustment (control group)
Number of subjects: 34
Study: 21443379

Group type: EXPERIMENTAL
Intervention: Novices receiving additional text explaining the animations
Number of subjects: 104

Group type: COMPARATOR
Intervention: Novices without additional text explaining the animations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Experts receiving additional text explaining the animations
Number of subjects: 104

Group type: COMPARATOR
Intervention: Experts without additional text explaining the animations
Number of subjects: 104
Study: 19514695

Group type: EXPERIMENTAL
Intervention: Antipneumococcal fluoroquinolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose beta-lactam/beta-lactamase inhibitor or second-/third-generation cephalosporin with azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics for hospitalized patients
Number of subjects: 0
Study: 16675478

Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (400 mg/m2 tegafur per day) for one year
Number of subjects: 274

Group type: COMPARATOR
Intervention: No treatment (surgery-alone group)
Number of subjects: 274
Study: 14722640

Group type: EXPERIMENTAL
Intervention: ICG‐PDR(0.5) with dosage 0.5 mg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ICG‐PDR(0.25) with dosage 0.25 mg/kg
Number of subjects: 16
Study: 11803864

Group type: EXPERIMENTAL
Intervention: Melbrosia treatment group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 9557910

Group type: EXPERIMENTAL
Intervention: 0.5 mg.kg(‐1) ephedrine intramuscularly
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.25 mg.kg(‐1) propofol intravenously
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.1 ml.kg(‐1) normal saline intravenously
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ephedrine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: propofol
Number of subjects: 90
Study: 7849542

Group type: EXPERIMENTAL
Intervention: Fluoride therapy (mean, 23 mg elemental F daily for approximately 18 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (38 osteoporotic females not receiving fluoride therapy)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluoride therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 3170393

Group type: EXPERIMENTAL
Intervention: amikacin 15.0 mg/kg administered in a single daily dose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: amikacin 11.0 mg/kg administered in a single daily dose
Number of subjects: 45

Group type: COMPARATOR
Intervention: amikacin 7.5 mg/kg administered twice daily
Number of subjects: 45
Study: 31804853

Group type: EXPERIMENTAL
Intervention: Google Cardboard headset (low-cost VR device)
Number of subjects: 48
Study: 29459408

Group type: EXPERIMENTAL
Intervention: Provision of TTR results
Number of subjects: 481

Group type: COMPARATOR
Intervention: No provision of TTR results
Number of subjects: 481